mci-196 has been researched along with Fatty Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babaya, N; Fujisawa, T; Hiromine, Y; Ikegami, H; Itoi-Babaya, M; Kawabata, Y; Kobayashi, M; Nojima, K; Noso, S; Ogihara, T; Shibata, M; Yamaji, K | 1 |
| Fujita, M; Irie, J; Itoh, A; Itoh, H; Kato, M; Kawai, T; Kawano, Y; Kobayashi, N; Kusumoto, Y; Morimoto, K; Morinaga, R; Nakajima, Y; Sugizaki, T; Tagawa, H; Tanaka, K; Watanabe, M; Yamada, S | 1 |
2 other study(ies) available for mci-196 and Fatty Liver
| Article | Year |
|---|---|
Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Blood Glucose; Body Weight; Carrier Proteins; Cholestyramine Resin; Diabetes Mellitus, Type 2; Disease Models, Animal; Epichlorohydrin; Fasting; Fatty Liver; Humans; Hyperlipidemias; Imidazoles; Insulin Resistance; Membrane Glycoproteins; Mice; Obesity; Resins, Synthetic; Weight Gain | 2007 |
Bile acid binding resin improves hepatic insulin sensitivity by reducing cholesterol but not triglyceride levels in the liver.
Topics: Animals; Bile Acids and Salts; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Insulin Resistance; Liver; Liver X Receptors; Male; Mice; Mice, Inbred Strains; Middle Aged; Orphan Nuclear Receptors; Retrospective Studies; Triglycerides | 2015 |